Avtor/Urednik     Štabuc, Borut
Naslov     Sistemsko zdravljenje raka trebušne slinavke
Prevedeni naslov     Chemotherapy for pancreatic cancer
Tip     članek
Vir     In: Pleskovič A, editor. Zbornik simpozija Kirurgija trebušne slinavke; 2002; Ljubljana. Ljubljana: Kirurška klinika, Klinični oddelek za abdominalno kirurgijo,
Leto izdaje     2002
Obseg     str. 164-76
Jezik     slo
Abstrakt     Pancreatic cancer is one of the most lethal cancers, with an overall 5-year survival rate of less than 5%. Surgery represents the only means to provide cure to patients with pancreatic cancer, though the 5-year survival is less than 20%. At time of presentation the majority of patients have locally advanced or metastatic disease which makes them unamenable for curative surgery. No effective therapy guidelines have been established for patients with pancreatic cancer. Although studies of adjuvant or neoadjuvant therapy suggest benefit, treatment protocols are far from being standardized. Adjuvant treatment post poned the incidence of recurrence during the first two years after surgery but it did not increase the cure rate. Chemoradiation therapy for locally advanced pancreatic cancer offers limited benefits and may be used as definitive therapy. Gemcitabine alone or in combination with other agents seems to be the first agent that has demonstrated improvement of disease related symptoms and survival in metastatic pancreatic cancer. New treatment modalities such as like gene therapy, antiangiogenic therapy, immunotherapy and more effective chemotherapies are needed to significantly improve outcomes.